NCT06318884 - A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions

Non-Hodgkin Lymphoma, B-cell

Interventions

DRUG

SCTB35 injection

SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.

Trial Locations (3)

100142

Beijing Cancer Hospital, Beijing

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Unknown

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY